1. Most Discussed
  2. Gainers & Losers
PBT 4.5¢

Brain Cancer Therapeutic Pipeline Review

  1. interestingtome

    1,847 Posts.
    1
    Brain Cancer Therapeutic Pipeline Review
    Brain Cancer Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com

    Dallas, TX (PRWEB) January 30, 2015

    The report "Brain Cancer – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Brain Cancer. Brain cancer is a tumour or cancerous development in the brain. A main brain tumor starts in the brain. A metastatic brain tumor starts anywhere else in the body and moves to the brain. Almost all tumors that begin in the brain do not spread to other parts of the body. Brain cancer can have a wide range of symptoms including seizures, sleepiness, confusion, nausea and vomiting, behavioral changes and muscle jerking. Brain tumours in children are different from those in adults and are often treated in a different way. Treatment for brain cancer should be individualized for each patient. In most cases of brain cancer surgery, radiation and chemotherapy are the main types of treatment.

    It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. Companies discussed in this Brain Cancer Pipeline Review H1 2015 report include AbbVie Inc., AngioChem Inc., Arrien Pharmaceuticals, LLC, BBB Therapeutics B.V., biOasis Technologies Inc., Bionomics Limited, Bristol-Myers Squibb Company, Cavion LLC, Critical Outcome Technologies Inc., CureFAKtor Pharmaceuticals, LLC, Diffusion Pharmaceuticals LLC, e-Therapeutics plc, Eisai Co., Ltd., Exelixis, Inc., GlaxoSmithKline plc, Hutchison MediPharma Limited, Merrimack Pharmaceuticals, Inc., Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences S.r.l., Neuralstem, Inc., Novartis AG, Oncology Research International Limited, Pfizer Inc., Philogen S.p.A., Phosplatin Therapeutics, Prana Biotechnology Limited, Puma Biotechnology, Inc., RadioRx, Inc., Sagetis Biotech, S.L., Sanofi, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Takeda Pharmaceutical Company Limited, ThromboGenics NV, Tocagen Inc., Zymeworks Inc.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.